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1. Introduction      
Human stem cells provide new hopes in the clinical treatment of a number of diseases, are 
excellent models for tissue and cell differentiation, and serve as the basis of new screening 
systems for drug development and toxicity. Regenerative medicine makes use of cells that 
can grow and differentiate to replace a damaged tissue. Hematopoietic stem/progenitor 
cells are successfully applied for bone marrow transplantation in otherwise lethal clinical 
conditions, while many other cell-based treatments are still experimental.  
Based on their basic features, we distinguish two major kinds of stem cells. Pluripotent stem 
cells, capable of differentiating to all types of the cells of human body, were first derived 
from early human embryos (HuES) and could be grown to provide cell lines with preserved 
pluripotent characteristics (Thomson et al., 1998). A recently discovered method of 
generating induced pluripotent stem (iPS) cells from differentiated cell types (Takahashi & 
Yamanaka, 2006) provides a potential to obtain autologous human stem cell lines without 
using embryonic tissues. In both cases a major concern, regarding therapeutic applications, 
is the formation of teratomas, consisting of numerous types of partially differentiated tissues 
(Reubinoff et al., 2000).   
Another major source of human stem cells is our own body. Although in a relatively small 
number, the so called “tissue-derived stem cells”, sometimes referred to as “adult stem 
cells”, are present throughout our life in various tissues and organs. The “stemness” of these 
cells, that is their actual stage of differentiation, depends on age, tissue origin and many 
other still unrecognized conditions. We know that the bone marrow or the cord blood of the 
neonate contains mostly hematopoietic progenitor cells, the skin, the liver or the intestine 
has a large number of repopulating epithelial progenitors, and even the muscle or the brain 
have dormant cells capable of tissue regeneration. Whether our body also contains early cell 
types similar to the embryonic stem cells, capable of differentiating into any tissue, is still an 
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unanswered question (Vieyra et al., 2005; Bussolati & Camussi, 2006; Bussolati & Camussi, 
2007; Satija et al., 2007).     
Under laboratory conditions undifferentiated cells from HuES or iPS cell lines grow in small 
clumps, but retain their undifferentiated form only under special conditions. They require 
media which contain a specific combination of growth factors, and in most cases the 
presence of appropriate feeder cells. The passage of the pluripotent cells can be performed 
by mild protease treatment and each cell type may require individual culturing and 
passaging conditions.  
The differentiation of the HUES or iPS cells is initiated spontaneously, as soon as these cells 
are removed from the special media and/or feeder cells, and placed into normal tissue 
culture plates or flasks. If the attachment of the cells is prevented, pluripotent stem cells 
generate so called embryoid bodies (EBs), which are complex, teratoma-like tissue structures 
with highly variable forms and tissue elements. If these EBs are placed onto tissue culture 
plates, they attach to the surface and start a further spontaneous differentiation process, by 
forming in many cases well recognizable tissue-types. Under these conditions, the formation 
of endothelial, epithelial, and neuronal cells, as well as of fibroblasts or cardiomyocytes can 
be observed.  
Tissue formation greatly depends on the culture conditions, which can be relatively well 
adjusted to obtain a specific enrichment of a desired tissue type. By applying protease-based 
cell separation, specific protein and nucleic acid extractions, or even by studying the formed 
tissues in situ, the pattern of protein expression can be followed during the stages of 
differentiation of stem cells.    
Well characterized human pluripotent stem cells thus indeed represent a great new tool for 
developmental studies, drug screening as well as cell- and gene-therapy applications. 
However, all these approaches usually require the development of efficient, stable gene 
delivery, and proper progenitor cell and tissue separation methods. Following of cell fate of 
differentiation by stably expressed marker proteins, or the introduction of new or corrected 
genes into stem cells, greatly facilitate and expand their research and therapeutic potential.   
Currently, the most widely applied methods for gene delivery into stem cells are based on 
the use of viral vector constructs. There are numerous efficient retrovirus- or lentivirus-
based methods which allow stable genomic incorporation of the foreign DNAs with high 
gene product expression levels. However, virus-based gene therapy technologies also have 
serious drawbacks, including safety concerns of virus production, and the preferential 
incorporation of foreign genes into active host gene loci, which may cause uncontrolled 
proliferation of the gene-modified stem cells (Schroder et al., 2002; VandenDriessche et al., 
2003). Non-viral gene delivery techniques are usually considered to be less efficient, 
however, with the emergence and refinement of the transposon based methods, they 
represent a valid alternative to viral applications (Ivics & Izsvak, 2004; Izsvak & Ivics, 2004; 
Ivics & Izsvak, 2006). In the following sections we detail the basic features, advantages and 
concerns of using transposon-based gene delivery into human stem cells. 
2. Transposon systems as genetic tools 
Transposons are “selfish” genetic elements that can move from one DNA locus to another 
either by a replicative or a non-replicative manner. They are widely present in the genome 
of all organisms and are also believed to be important driving forces for evolution 
(Kazazian, 2004; Hedges & Batzer, 2005; Feschotte & Pritham, 2007). The human genome 
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carries a significant proportion of transposable elements: it is estimated that ca. 45% of our 
genetic material is made up of transposons (Biemont & Vieira, 2006; Mills et al., 2006; 
Wicker et al., 2007; Goodier & Kazazian, 2008). The majority of these belong to the Class I 
retrotransposons which contain currently active elements moving in our genome by the 
replicative “copy and paste” mechanism (Mills et al., 2007). Although applications using 
certain retrotransposons as genetic tools exist (Uren et al., 2005; Ostertag et al., 2007), their 
obvious disadvantages (the potential remobilization of the delivered transgene and the high 
mutational rate resulting from reverse transcription) make them less favorable as genetic 
delivery vehicles. 
As opposed to retrotransposons, the Class II DNA transposons make up a relatively small 
portion (~3%) of the human mobile elements (Feschotte & Pritham, 2007) and currently none 
of them have been shown to be active in our genome (Collier & Largaespada, 2007; Izsvak et 
al., 2010). They move by the non-replicative “cut and paste” mechanism and their active and 
modified forms have been widely used in genetic analysis of lower (mostly invertebrate) 
model organisms including Drosophila species and Caenorhabditis elegans (Mates et al., 2007). 
Various gene trapping or insertional mutagenesis experiments proved that transposon 
based gene delivery is an efficient system, however, lacking similar genetic methods in 
mammalian cells was an obvious disadvantage. 
The first breakthrough in this field was the resurrection of Sleeping Beauty (SB), an artificial 
Tc1/Mariner-type transposon system “remastered” from old fish transposon fossils, and the 
 
Fig. 1. The principle of gene delivery by the Sleeping Beauty transposon system. 
The gene of interest in a transcription unit (here a puromycin resistance gene, “puro”) is 
placed between the transposon sequences (IR-DR(L) and-(R): inverted repeat – direct repeat 
Left and Right sequences). Such an engineered transposon vector is co-transfected with a 
transposase expressing plasmid into the cells (left panel) and selected by puromycin for 10 
days. Following selection, live cells are visualized by Giemsa-staining. The control reaction 
is carried out using a mutant transposase (right panel) to detect the level of random 
integration without transposition. As shown in this experiment, transposon based gene 
delivery is several orders of magnitude higher than the background random integration. 
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proof of principle that it was active in mammalian cells (Ivics et al., 1997). Its structure is 
relatively simple (Figure 1) and an elegant way of creating a non-autonomous version by 
separating the transposase from its targets (the terminal inverted repeat sequences) made it 
an easily controllable system and therefore an attractive tool for functional genetics (Izsvak 
et al., 2000). Nevertheless, its efficiency in gene delivery at that stage was still behind that of 
viral vectors, the canonical genetic vehicles used in human applications. 
Following the reconstruction of SB, other DNA transposons were shown to be active in 
mammalian cells, including transposons isolated from other species (such as piggyBac from 
the insect Trichoplusia ni (Ding et al., 2005) and Tol2 from medaka fish (Balciunas et al., 
2006)), and another “awakened” Tc1/Mariner transposon called Frog Prince (Miskey et al., 
2003). However, transposons are naturally not selected for maximal activity in order to 
minimize the insertional mutagenesis in the host genome and the reconstructed ones were 
not expected to be the most active forms either. It was then shown that it is possible to create 
hyperactive versions of these transposons by molecular engineering (Zayed et al., 2004; Baus 
et al., 2005; Pledger & Coates, 2005), and such variants would likely represent more efficient 
genetic vehicles. 
Recently, a 100 times more active form of SB (SB100x) was created, and its activity was 
already comparable to the most efficient viral vectors (Mates et al., 2009). The system could 
also tolerate practically any inserted sequence and the cargo size capacity is less limited than 
that of viral vectors: it can efficiently move inserts of >8 kb, although transposition efficiency 
decreases with larger cargo size (Izsvak et al., 2010). Unexpectedly, the amount of the 
transposase seemed to be a more critical issue: the transposition efficiency paradoxically 
decreases when the amount of transposase raises beyond a certain level, a phenomenon 
called overproduction inhibition (Lohe & Hartl, 1996). All of the used DNA transposons 
seem to share this feature but the careful titration to set up the optimal transposase level 
provided evidence that among them, SB was the most efficient system in conditions when 
the amount of transposon DNA is limiting (Grabundzija et al., 2010). This finding made the 
SB system attractive to many applications where transgene delivery into hard-to-transfect 
cell types is required, including embryonic stem cells (see Part 3). In addition, the lack of 
endogenous copies in vertebrate (particularly in human) genomes represents an important 
safety issue as it ensures that the integrated transgenes are not being remobilized (Ivics et 
al., 1997; Ivics et al., 2004). Such attractive characteristics prognosticated that the SB100x 
transposon version would likely represent a method of choice when carrying out gene 
delivery into mammalian cells. 
The “technology transfer” from invertebrates to use transposons for genetic manipulations 
had an immediate effect on mammalian forward genetic screens: SB transposon was 
successfully used in cancer genetics in order to identify genes involved in certain malignant 
phenotypes (Carlson et al., 2005; Collier et al., 2005; Collier & Largaespada, 2005; Starr et al., 
2009). In addition, various insertional mutagenesis screens could be set up, often exploiting 
the phenomenon of “local hopping” when the transposon preferentially moves in the 
vicinity of the donor chromosomal locus (Dupuy et al., 2005; Lu et al., 2007; Takeda et al., 
2007; Takeda et al., 2008). This characteristic seems to be a common feature of “cut and 
paste” transposons and could be very useful for saturation mutagenesis of particular 
chromosomal regions (Luo et al., 1998; Fischer et al., 2001; Carlson et al., 2003; Carlson & 
Largaespada, 2005; Keng et al., 2005). For SB, however, this “local hopping” does not appear 
to be very stringent since the transposition intervals are higher than that of other DNA 
transposons (Carlson et al., 2003). Nevertheless, the SB transposon was successfully 
www.intechopen.com
Use of the Transposon-Transposase System  
for Stable Genetic Modification of Embryonic Stem Cells   
 
263 
established as an efficient genetic tool for forward genetics in mammals, similarly to the P 
element based applications in Drosophila (Ryder & Russell, 2003; Miskey et al., 2005).        
When considering gene therapy applications in human, however, efficiency is only one of 
the important issues that must be addressed before a genetic system becomes approved. For 
example, an important drawback of the efficient viral methods are their non-random 
integration profile: they integrate favorably into transcription units, often preferably into 5’ 
regions of active genes (Schroder et al., 2002; Bushman, 2003; VandenDriessche et al., 2003; 
Wu et al., 2003; Narezkina et al., 2004). To a lesser extent, this adverse site preference is also 
the characteristic of some transposons, including piggyBac (Wilson et al., 2007) and Tol2 
(Grabundzija et al., 2010). On the other hand, Sleeping Beauty seems to be a favorable system 
from this point of view: the integration profile was revealed to be very close to random on 
the genomic level (Vigdal et al., 2002; Liu et al., 2005; Yant et al., 2005). This important 
feature significantly lowers the risk of insertional mutagenesis which is beneficial for gene 
therapy applications. 
Other issues include the potential silencing of the transgene which could hinder the 
applicability of viral vectors (Ellis, 2005). Embryonic stem cells, for instance, have clear 
molecular defense mechanisms against viral promoter sequences (Meilinger et al., 2009; 
Rowe et al., 2010). When addressing this question for the SB transposon, it was revealed that 
the effect of silencing depends rather on the cargo sequence and not on the vector itself 
(Garrison et al., 2007; Zhu et al., 2010). All these encouraging characteristics further 
supported the use of SB as a tool for gene therapy and provided the basis for the first clinical 
trial initiated by a non-viral vector: SB is used in the treatment of a B-lymphoid malignancy 
by ex vivo genetically modified autologous T-cells (Williams, 2008). The outcome of the trial 
will apparently provide valuable information on the efficiency and biosafety of transposon 
based gene delivery and could potentially set new standards in gene therapy application, 
especially since the use of the SB transposon system was recently shown to be applicable 
also in embryonic stem cells (Wilber et al., 2007; Orban et al., 2009). This promising scenario 
undoubtedly played a role in that the SB100x transposase version was recently nominated as 
the “Molecule of the Year” in 2009 (http://www.biotechniques.com/news/Sleeping-
Beauty-named-Molecule-of-the-Year/biotechniques-187068.html?autnID¼191663). 
3. Selecting transgene expressing stem cells after transposition 
The basis of any successful gene therapy applications is undeniably an efficient and stable 
gene delivery into stem cells. For this purpose, viral based applications were traditionally 
favored as viruses have been selected through evolution to efficiently deliver genetic 
material (DNA or RNA) into their host cells. However, two negative aspects of their usage 
made non-viral approaches favorable despite their lower efficiency: the biased integration 
profile of viral vectors, and the limitation of the cargo size due to the packaging constraint of 
the virus particles. The latter one is an important issue when considering relatively large 
cDNAs of certain human genes, or the need for simultaneous delivery of more cDNAs into 
one sample. Although potentially overcoming these problems, the uses of first generation 
non-viral vectors were clearly several magnitudes less efficient than their peer viral 
counterparts. With the emerging hyperactive transposons, however, gene delivery efficiency 
was partly resolved. Nevertheless, the use of any transposon system requires the 
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transfection of DNA into the host cells, and several applications involve cell types that are 
generally difficult to transfect, including embryonic stem cells. Albeit various transfection 
protocols are currently available, it is infrequent to achieve higher than 50-80% transfection 
efficiency without severely affecting cell survival, therefore efficient and preferably non-
invasive selection protocols should always be worked out to establish homogenous 
transgene expressing stem cells following transfection and transposition. 
One widely used selection method is to apply chemical selection (e.g. antibiotics) to enrich 
for transgene expression. This approach usually serves well if cell source is not limiting and 
when the chemical selection does not significantly perturb cell physiology. Embryonic stem 
cells, however, represent much more sensitive cell types and if later clinical applications are 
taken into account, it has to be borne in mind that the precious cells on which the therapy 
can begin with will most likely come from a limited source. Therefore, a selection must be 
efficient and at the same time, the least invasive procedure. The commonly used drugs, 
however, could induce undesired gene expression profiles, or initiate partial differentiation 
of the stem cells. If chemical selection is inescapable, the cells must always be examined 
carefully whether they retained their pluripotency status at least by immunostaining for 
accepted surface markers or preferably also by scrutinizing their differentiation potential 
(Duan et al., 2007; Tomescot et al., 2007; Orban et al., 2009). Moreover, since the use of a 
marker gene (eg. an antibiotic resistance gene) evidently means a use of a larger cargo, the 
overall gene delivery efficiency will decrease. An elegant way of reducing this problem is 
the use of viral linker peptides between cDNA sequences instead of independent 
transcription units (see Part 4), but the potentially altered genetic profiles still disfavors such 
selection approaches, if possible. 
Another unexpected problem of chemical selection originates from the multidrug resistance 
phenotype, more precisely, from the presence of MDR-ABC transporters, especially the 
ABCG2 protein. It is now well established that this multidrug transporter is present in 
embryonic stem cells and is responsible for the so called “side population” phenotype of a 
wide variety of tissue-derived stem cells (Zhou et al., 2001; Sarkadi et al., 2010). The exact 
function of ABCG2 in these cell types is not fully elucidated yet but numerous evidence 
points to its role to protect these valuable sanctuaries against various noxae by extruding 
undesired drugs out of the cells (Figure 2). Clearly, the presence of such defense mechanism 
can work against chemical selection since the increase of endogenous ABCG2 expression 
could work against the enrichment of transgene expressing stem cells, e.g. by pumping out 
puromycin from stem cells (Takenaka et al., 2007). Also, antibiotic selection may greatly 
increase MDR-ABC protein expression as a stress-related response (Theile et al., 2010).                   
Another approach for the enrichment of transgene expression is the use of fluorescent 
proteins as markers. The genetically modified, fluorescent stem cells can be separated by 
FACS (Fluorescent Activated Cell Sorting) analysis or positive clumps can be sequestered in 
sterile conditions using fluorescent microscopy. In our laboratory, we have routinely 
established different transgene expressing human embryonic stem cell clones, usually 
combining both methods (Figure 3). Although less invasive than chemical selection, this 
procedure can be more laborious and time consuming. Moreover, as strongly expressing 
cells have a higher chance of being selected, this method inherently favors stem cells with 
higher copy numbers which should be considered if a certain application requires low copy 
number (or even single copy number) clones. Nevertheless, this approach is still less 
www.intechopen.com
Use of the Transposon-Transposase System  
for Stable Genetic Modification of Embryonic Stem Cells   
 
265 
invasive as a chemical selection, even though the problem of delivering another transgene 
additionally to the selection marker again places a burden by the increase of the cargo size, 





Fig. 2. Expression of the ABCG2 membrane transporter in a human embryonic stem cell 
clump. 
HUES9 cells were immunostained with the 5D3 anti-ABCG2 antibody (green); the Hoechst 
33342 dye (blue) was used to visualize cell nuclei. The confocal microscopy image clearly 
shows that ABCG2 is localized in the plasma membrane of all examined cells. Scale bar 
represents 20 μm. 
 
To combine the advantages of viral vectors and transposons, several groups attempted to 
create genetic chimera vehicles, using non-integrating virus forms with the SB system 
(Bowers et al., 2006; Staunstrup et al., 2009; Vink et al., 2009; de Silva et al., 2010b). This 
approach can overcome the inefficient delivery often associated with transfection of DNA 
into certain cell types, and presents the favorable transgene integration profile provided by 
the SB transposase. Such hybrid vectors certainly open new vistas in gene therapy, although 
rigorous testing should still be carried out to carefully examine the safety and efficiency of 
these methods. There is one study claiming that the chimera vector of a Herpes simplex 
virus and a hyperactive version of SB loses its transposition “hyperactivity” in vivo (de Silva 
et al., 2010a). However, as this study used an earlier version of the transposase, the results 
should be carefully repeated with the new SB100x system which provides a far more robust 
gene delivery in vivo than any previous transposons, therefore could potentially overcome 
this negative side effect.   
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Fig. 3. Cloning of the transgene expressing embryonic stem cells following transposon 
mediated gene delivery. 
(A) GFP expression cassette is delivered into HUES9 cells by the SB transposon system. The 
image is taken 48 hours post-transfection, showing a heterogeneous cell population of a 
clump on mouse embryonic feeder cells. (B) Enrichment of transgene expressing cells by 
manual sequestration of GFP positive cells using fluorescent microscopy. (C) The results of 
cloning GFP expressing stem cells by FACS from clumps in stage (B). Phase contrast 
fluorescence microscopy images, x40 magnification. 
4. Applications of transposon based gene delivery in embryonic stem cells 
HuES cells represent excellent models for cell and tissue differentiation, however, directing 
the genetic program toward a certain lineage is often challenging. For various applications, 
such as pharmacological screening models, the aim is to achieve a reasonable enrichment of 
a given tissue type among the various progeny of cell types. Current methods often apply 
endogenous morphogenic proteins or invasive chemicals to obtain the tissue(s) of interest, 
however, the use of such artificial chemical cocktails could have serious side effects, 
including undesired gene expression profiles and/or distorted differentiation pathways. On 
the other hand, the alternatively used spontaneous differentiation of HuES cells (e.g. via the 
embryoid body pathway) is a stochastic process and the efficiency of obtaining a particular 
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cell type is often very low. In addition, some tissue types are difficult to recognize solely by 
morphological signs, and other – often invasive – molecular identification methods are 
necessary to apply.  
In our laboratory, we are examining cardiovascular differentiation, with an obvious 
advantage of having a clearly recognizable phenotype at the end of differentiation. Such 
contracting cell populations can be found following spontaneous differentiation, however, 
their number can vary significantly. To increase the efficiency of cardiac cell detection, we 
have developed a method using a specific “double-feature” promoter (Orban et al., 2009). It 
is based on the unprecedented characteristic of a CAG promoter variant: as being a 
constitutive promoter, it is expressed in all tissue types which was the reason why it was 
chosen to drive the expression of a fluorescent reporter gene. On the other hand, the 
transcriptional activity of this CAG variant becomes extremely high in differentiated 
cardiomyocytes, providing an excellent platform of selecting these cell types based on the 
intensity of the fluorescent signal. This behavior is also very useful when a transposon based 
gene delivery is applied: the “double-feature” promoter is used to identify the transgene 
expressing undifferentiated cells after transfection and later on, it offers the possibility to 
select for differentiated cardiomyocytes (Figure 4). This approach represents a great 
advantage because up to our knowledge, no commercially available antibodies against 
cardiac specific cell surface markers exist which would allow gentle separation of these cell 
types. Moreover, as this promoter is less prone for silencing (Chung et al., 2002; Xia et al., 
2007), the loss of cells containing inactive transgene copies is also significantly reduced. The 
background of this “double-feature” phenomenon is still under investigations, and 
deciphering its structural basis could lead to a promising scenario of creating promoters 
with different tissue specificities. Such achievement would represent a great technological  
 
Fig. 4. Using the “double-feature” CAG promoter to visualize cardiomyocytes. 
White arrows depict contracting cardiomyocytes arising from spontaneously differentiated 
HUES9 cell clones expressing either CAG promoter- (SB-CAG-GFP) or EF1α promoter-
driven (SB-EF1α-GFP) transgene. Note that in SB-EF1α-GFP cells, the entire population 
expresses GFP at low level almost uniformly, whereas in SB-CAG-GFP cells, GFP expression 
in cardiomyocytes is extremely high as compared to the surrounding tissues; see further 
details in text. Phase contrast fluorescence microscopy images, x40 magnification. 
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breakthrough as tissues lacking easily recognizable morphological signs could be separated 
without invasive identification protocols; and the SB transposon based transgene delivery 
would ensure the lowest possible risk of mutagenesis by its random integration profile. 
The technology of generating iPS cells is an obvious example where the use of transposons 
as genetic vehicles is clearly beneficial due to the large cargo size. For efficient 
reprogramming of fibroblasts, at least 4 transcription factors need to be overexpressed 
(Takahashi & Yamanaka, 2006) which places a heavy burden on the otherwise also not very 
efficient method itself. The use of independent transcription units are clearly represent too 
large cargos; the use of IRES (Internal Ribosome Entry Site) sequences instead also faces the 
problem of inefficient and non-equimolar expression of several cDNAs. An elegant way of 
overcoming this issue is the use of the 2A viral linker peptides: it basically allows to 
establish a polycistronic mRNA from which separate peptide chains can be translated 
equimolarly in eukaryotic systems (Szymczak et al., 2004). However, when considering an 
additional selection marker, the length of such a cargo (~7 kb or higher) still pushes the 
packaging limits of most viral vectors so the need to deliver such a long transgene calls for 
the use of transposons. Indeed, the piggyBac system was applied to successfully establish 
pluripotent iPS cell lines (Kaji et al., 2009; Woltjen et al., 2009). Nevertheless, some 
disadvantages of the piggyBac system, e.g. the non-random integration profile (Wilson et al., 
2007) or the presence of endogenous elements potentially capable of remobilizing the 
transgene (Newman et al., 2008) clearly awaits for the use of another, technically safer 
system such as the SB transposon. In addition, for any gene therapy application constrained 
by the size of a large human transgene cDNA calls for the application of transposons, 
preferably the SB system. 
5. Conclusion 
Embryonic stem cells represent promising new tools in the clinical treatment of various 
diseases, and in the meantime, they provide emerging new systems in modeling tissue 
differentiation and pharmacological screens for drug development and toxicity. With the 
development of laboratory protocols for the maintenance of these cell types, it is also 
important to work out efficient and biologically safe methods for gene delivery as it often 
represents the “take-off” point of any successful work with HuES cells. Among the non-viral 
gene delivery techniques, the hyperactive Sleeping Beauty transposon-transposase system 
represents a particularly attractive method with several advantages. It is a powerful gene 
delivery methodology with the least currently known genotoxic effects mainly due to its 
random integration profile at the genomic level. Also, it is a favorable genetic vehicle in 
terms of cargo capacity, tolerating relatively long transgene sequences. Moreover, as 
opposed to most viral vectors, the transposon sequences are less prone to epigenetic 
silencing which also provides the background for a long-term stable transgene expression. 
The last but not the least argument for the use of this transposon system is the cheaper and 
easier production of vector DNA, especially when clinical-grade applications are 
considered. Taken together, all these favorable characteristics definitely make the 
hyperactive SB system an attractive alternative for any gene therapy purposes, although, as 
it is the case with any other newly developed techniques, further investigations are still 
necessary to validate its biological safety in clinical applications. 
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